National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 3164 [2021-00573]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
3164
Federal Register / Vol. 86, No. 9 / Thursday, January 14, 2021 / Notices
immunotherapy using autologous
human T cells transduced with
lentiviral vectors, wherein the viral
transduction leads to the expression of
a CAR that targets CD33 (comprised of
the CD33-binding domain referenced as
Hu195 or hP67.6 in the invention as
well as an intracellular signaling
domain), for the prophylaxis or
treatment of CD33-expressing cancers.
For clarity, ‘‘CD33-specific logic-gated
CAR-based immunotherapy’’ means
therapies where the CAR-expressing T
cells recognize CD33 and are engineered
to respond to one or more additional
antigens (but not necessarily all of the
antigens).
2. The development of a CD33specific logic-gated CAR-based
immunotherapy using allogeneic human
NK cells transduced with retroviral
vectors, including but not limited to
lentiviral vectors, wherein the viral
transduction leads to the expression of
a CAR that targets CD33 (comprised of
the CD33-binding domain referenced as
Hu195 or hP67.6 in the invention as
well as an intracellular signaling
domain), for the prophylaxis or
treatment of CD33-expressing cancers.
For clarity, ‘‘CD33-specific logic-gated
CAR-based immunotherapy’’ means
therapies where the CAR-expressing NK
cells recognize CD33 and are engineered
to respond to one or more additional
antigens (but not necessarily all of the
antigens).
These technologies disclose therapies
to treat AML by utilizing CARs that
recognize AML cells through a binder
for CD33. The CD33 binders are known
as Hu195 or hP67.6. CD33 is a well
validated immunotherapeutic target that
is expressed on the surface of malignant
cells, most notably on the surface of
acute myelogenous leukemia (AML)
blasts.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
VerDate Sep<11>2014
20:43 Jan 13, 2021
Jkt 253001
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: January 7, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–00637 Filed 1–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Production of Adjuvants
Mimics (Topic 093) (For SBIRs Phase I)
Date: February 1, 2021.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maggie A. Morris Fears,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, 301–761–5444,
maggie.morrisfears@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Adjuvant Discovery for
Vaccines and for Autoimmune and Allergic
Disease (Topic 092) (For SBIRs Phase I).
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Date: February 1, 2021.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maggie A. Morris Fears,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, 301–761–5444,
maggie.morrisfears@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase II: Adjuvant Discovery for
Vaccines and for Autoimmune and Allergic
Disease (Topic 092) (For SBIRs Phase II).
Date: February 1, 2021.
Time: 2:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maggie A. Morris Fears,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, 301–761–5444,
maggie.morrisfears@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 8, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–00573 Filed 1–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
E:\FR\FM\14JAN1.SGM
14JAN1
]]>Agencies
[Federal Register Volume 86, Number 9 (Thursday, January 14, 2021)]
[Notices]
[Page 3164]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-00573]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
I: Production of Adjuvants Mimics (Topic 093) (For SBIRs Phase I)
Date: February 1, 2021.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maggie A. Morris Fears, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, 301-761-5444, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
I: Adjuvant Discovery for Vaccines and for Autoimmune and Allergic
Disease (Topic 092) (For SBIRs Phase I).
Date: February 1, 2021.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maggie A. Morris Fears, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, 301-761-5444, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
II: Adjuvant Discovery for Vaccines and for Autoimmune and Allergic
Disease (Topic 092) (For SBIRs Phase II).
Date: February 1, 2021.
Time: 2:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maggie A. Morris Fears, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, 301-761-5444, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 8, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-00573 Filed 1-13-21; 8:45 am]
BILLING CODE 4140-01-P
